Meakin adjuvant regimen premenopausal patients breast cancer experience ovarian ablation prednisolone adjuvant therapy premenopausal patients breast carcinoma tolerability morbidity Thirty patients years equal years years underwent mastectomy/lumpectomy axillary clearance local irradiation ovarian irradiation prednisolone therapy mg times years Patients months first years months Follow-up years median years Twenty-four patients alive patients therapy side-effects mean s.e.m gain cent therapy Nineteen patients prednisolone period months median months median length time steroids years years regimen acceptable level patient tolerability low chronic morbidity rate alternative systemic cytotoxic therapy 